Thus, a combination of trastuzumab plus MRK-003 GSI could benefit those women with recurrent, or possibly resistant, ErbB-2-positive breast cancer ultimately to reduce or eliminate disease progression and deaths by simultaneously inactivating two critical prosurvival and antiapoptotic pathways such as ERK1/2 and AKT1. This evidence concerns the gene AKT1 and breast cancer.